
Ionis Pharmaceuticals, Inc.
IONSNASDAQHealthcare● Active
$73.54
$-0.94(-1.26%)
Market Cap$12.2B
P/E Ratio—
52W High$86.74
52W Low$34.78
Ionis Pharmaceuticals, Inc. (IONS) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IONS · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.38B) | ($0.45B) | ($0.37B) | ($0.27B) | ($0.03B) |
| Depreciation & Amort. | $0.02B | $0.02B | $0.02B | $0.02B | $0.02B |
| Stock-Based Comp. | $0.00B | $0.13B | $0.11B | $0.10B | $0.12B |
| Change in Working Capital | ($0.05B) | ($0.21B) | ($0.08B) | $0.01B | ($0.11B) |
| Net Cash from Operations | ($0.27B) | ($0.50B) | ($0.31B) | ($0.27B) | $0.03B |
| Investing Activities | |||||
| Capital Expenditure | ($0.05B) | ($0.05B) | ($0.03B) | ($0.02B) | ($0.02B) |
| Purchases of Investments | ($1.92B) | ($1.85B) | ($1.77B) | ($1.49B) | ($1.13B) |
| Sales of Investments | $1.70B | $1.77B | $1.58B | $0.99B | $1.34B |
| Net Cash from Investing | ($0.28B) | ($0.13B) | ($0.21B) | ($0.26B) | $0.19B |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.48B | ($0.04B) | $0.09B | ($0.05B) | $0.31B |
| Net Cash from Financing | $0.68B | $0.48B | $0.64B | ($0.06B) | $0.25B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.32B) | ($0.55B) | ($0.34B) | ($0.29B) | $0.01B |
| FCF Margin %(computed) | -33.90% | -77.46% | -42.60% | -50.13% | 1.59% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Ionis Pharmaceuticals, Inc. data
About Ionis Pharmaceuticals, Inc. (IONS) Cash Flow Statement
Ionis Pharmaceuticals, Inc. generated operating cash flow of ($0.27B) and free cash flow of ($0.32B) for 2025 — a FCF margin of -33.90%. Capital expenditure was ($0.05B).
Frequently asked questions
IONS · 4 questionsIonis Pharmaceuticals, Inc. generated free cash flow of ($0.32B) for 2025, up 41.4% year-over-year.
IONS free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10